Blog | BioInformant

Hematopoietic Stem Cells: What Diseases Can these Stem Cells Treat?

December 18, 2025 By Cade Hildreth, Founder & President Leave a Comment

Hematopoietic stem cells (HSCs) are defined as stem cells that have a preference for becoming cells of the blood and immune system, such as white blood cells, red blood cells, and platelets. Found in the peripheral blood and bone marrow, hematopoietic stem cells are also present in plentiful supply within the umbilical cord blood of newborn babies.

For the past thirty years, cord blood has been used within transplant medicine, including for the treatment of leukemia and other blood diseases. For most conditions in which a bone marrow or peripheral blood stem cell transplant is an option, a cord blood transplant is a potential alternative.

Hematopoietic Stem Cells

In this article:

Human Cord Blood Cells
Common Diseases Treatable with Cord Blood Transplant
Allogeneic and Autologous Transplants
Diseases Treatable with Hematopoietic Stem Cell Transplant in the Future

[Read more…]

4 Major Areas of Commercialization for iPS Cells

December 18, 2025 By Cade Hildreth, Founder & President Leave a Comment

Since the discovery of induced pluripotent stem cells in 2006, a great deal of basic research has been done to understand how to produce, manipulate, and utilize the stem cell type. In addition to this important basic research, a great deal of applied (“translational”) results has been done with the cell type. Induced pluripotent stem cells (also called iPS cells or iPSCs) are revolutionizing regenerative medicine because they represent a potential route for producing patient-specific stem cells for research or clinical use.

In the future, iPS cells will facilitate progress in personalized medicine by allowing a patient to use his or her own cells. In addition, iPSCs also show great promise in other areas, such as phamaco-toxicological screening, by allowing disease modeling and safety assessment of potential new drugs under development, in short, facilitating the study of a “disease in a dish.”

[Read more…]

Cell Therapy Industry Contractions: Companies Curtail Ambitious Programs

December 18, 2025 By BioInformant Team Leave a Comment

Over the past 60 days in the cell therapy sector, one of the most striking trends has been strategic pullbacks and restructuring by formerly committed companies, even as core innovation continues elsewhere in the biotech ecosystem. After years of heavy investment and high expectations, several major players have opted to re‑evaluate or wind down their cell therapy operations, citing competitive pressures, shifting priorities, and capital allocation decisions.

These moves have sent ripples across the industry and prompted fresh discussion about the direction of advanced therapies in the years to come. [Read more…]

Curi Bio Secures $10M Series B to Scale Human-Relevant iPSC-Based Preclinical Platforms and Advanced Data Analysis for Drug Discovery

December 16, 2025 By BioInformant Team Leave a Comment

Financing led by DreamCIS will accelerate and expand development of the company’s industry-leading integrated platform, combining human iPSC-derived cells, advanced biosystems, and functional data analysis to de-risk and accelerate therapeutic development.

SEATTLE — Curi Bio, a leader in delivering human-relevant functional data for drug discovery and development, today announced the close of a $10 million Series B financing round. The round was led by DreamCIS, the leading contract research organization based in Seoul, South Korea, offering comprehensive services for clinical research and regulatory affairs. This strategic partnership is poised to accelerate the translation of Curi Bio’s human-relevant platforms into global clinical success. [Read more…]

BMS Makes a Bold Leap into CAR-T Buying Orbital Therapeutics for $1.5B

December 16, 2025 By Cade Hildreth, Founder & President Leave a Comment

On October 10th, 2025, Bristol Myers Squibb (BMS) announced its plan to acquire Orbital Therapeutics for 1.5 billion dollars in cash. This decisive move places BMS directly into the rapidly growing in vivo CAR T sector. Orbital Therapeutics, based in Cambridge, Massachusetts, has been advancing a next generation RNA platform that is designed to reprogram immune cells inside the body instead of relying on the traditional practice of engineering cells outside the body.

Central to the acquisition is Orbital’s lead candidate, OTX 201. This investigational treatment uses circular RNA delivered through lipid nanoparticles to encode a CD19 targeted CAR. The goal is to create CAR expressing cells directly within the patient. This approach could reshape the entire cell therapy landscape by eliminating complex external manufacturing steps. [Read more…]